E2OPEN Parent Holdings Inc (ETWO):

Play Episode

4min

Proactive - Interviews for investors

Nextech3D.ai unveils AI-powered customer service chatbot, ushering new era of customer engagement

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to introduce the company’s latest innovation: an AI-powered customer service chat agent designed to enhance customer interactions and drive sales. This cutting-edge virtual assistant, integrated directly into Nextech3D.ai’s website, features advanced voice technology from Eleven Labs, enabling natural, human-like conversations. The AI chatbot is engineered to streamline customer support with a range of capabilities, including appointment scheduling, a dynamic knowledge base tailored to Nextech’s services, and seamless transitions to live representatives when needed. By leveraging artificial intelligence, Nextech aims to provide a frictionless, efficient, and engaging experience for its customers. Gappelberg emphasized that the adoption of AI chat agents marks a pivotal step in Nextech3D.ai’s evolution into an AI-first technology company, positioning it to compete at the highest level. The chatbot is not just a tool for customer engagement but also a powerful lead generation asset, automating appointment bookings and capturing high-quality leads to optimize service efficiency. By integrating this AI assistant, Nextech ensures that customers receive accurate, brand-aligned responses to their inquiries while maintaining the option for human support when necessary. With this move, Nextech3D.ai reaffirms its commitment to innovation and sets a new standard for AI-driven customer interactions. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

Digitalbox CEO James Carter on strong 2024 growth and 2025 outlook

Digitalbox PLC (AIM:DBOX) CEO James Carter takes Proactive's Stephen Gunnion through the company’s strong 2024 performance and its strategy heading into 2025. The company delivered a 31% increase in revenue during the year, with Carter describing it as “a good turnaround year.” He pointed to audience growth that outperformed broader news media trends, and revenue growth that exceeded global digital advertising market averages. Carter credited the success to the strength of Digitalbox’s brands and editorial teams, as well as the company’s in-house Graphene Ad Stack technology. “The editorial teams are really very well tuned into what their audiences want,” he said. Among standout performers were TV Guide, which achieved 90% traffic growth in Q4 following a move to a web app format, and The Tab, which benefited from social media asset integration. The Poke also saw a 22% increase in traffic following increased content investment. The company expanded its portfolio from six to eight brands in 2024, aiming to reach ten by the end of 2025. Looking ahead, Carter said 2025 is in line with expectations so far, and Digitalbox remains “cautiously optimistic” amid projected 10% growth in the digital ad market. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #Digitalbox #JamesCarter #MediaGrowth #DigitalAdvertising #TVGuide #TheTab #OnlineMedia #RevenueGrowth #AdTech #MediaBrands #InvestorUpdate #ProactiveInvestors

Proactive - Interviews for investors

Opioid-Free pain relief: AFT’s global expansion strategy

AFT Pharmaceuticals Ltd Managing Director Dr Hartley Atkinson talked with Proactive at the AIM's Small and Midcap Conference about the company's unique approach to drug development, its expanding global footprint, and what lies ahead in 2025. AFT Pharmaceuticals is focused on creating pharmaceuticals "with a difference," targeting unmet needs and reducing reliance on opioids. “We don’t sell anything we don’t believe in,” said Dr Atkinson, highlighting the importance of alternatives to opioid treatments. One of the company’s key analgesic products helps avoid opioid use — a particularly timely innovation in light of the global opioid crisis. Dr Atkinson discussed the company’s core markets, with a strong presence in New Zealand and Australia, generating approximately 150 million in revenue. AFT also maintains operations in Asia and now exports to around 80 countries. The company has experienced sustained growth, having quadrupled in size over the past decade and doubled in the last five years. AFT has established six new affiliates across regions including Singapore, Hong Kong, South Africa, Canada, the UK, and Europe. Looking ahead, the company plans several product launches across Australia and New Zealand and anticipates five drug launches in China — the world’s second-largest pharmaceutical market. “For us, that’s going to be an interesting journey,” Atkinson added. #AFTPharmaceuticals #OpioidAlternatives #PharmaceuticalInnovation #ChinaPharma #DrugDevelopment #HealthcareGrowth #ASXStocks #BiotechInvesting #GlobalHealthcare #PharmaExpansion

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Followers	2
Posts	172
Boards Moderated	0
Alias Born	10/24/2024

Volume:	686,054
Day Range:	2.05 - 2.25
Bid:
Ask:
Last Trade Time:	7:00:00 PM EDT
Total Trades:	5,073

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ETWO Detailed Quote

Recent ETWO News

More ETWO News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ETWO News

Go Ad-Free